

Author Index

- Abel DJ, 351
 Agnew J, 330
 Alexander GC, 368
 Allen RL, 351, 494
- Ballachanda BB, 1
 Beamer SL, 429
 Beauchaine KL, 337
 Beck LB, 181
 Bishop RD, 214
 Boppana SB, 283
 Branham K, 84
 Britt WJ, 283
- Cacace AT, 239
 Calder JH, 76, 514
 Campbell KCM, 361
 Carlson-Smith C, 446
 Carpenter MD, 494
 Cestnick L, 501
 Cevette MJ, 323
 Champlin CA, 46, 64, 489
 Cherry R, 52
 Christ A, 390
 Clukey C, 411
 Cord MT, 475, 540
 Cousins JP, 239
 Cox RM, 368
 Cranford JL, 36, 494
 Cruickshanks KJ, 67
- Dahle AJ, 283
 Dalebout SD, 12
 Daly DM, 454
 Daniloff RG, 454
 Davenport ML, 446
 DeChicchis AR, 36, 97
 Dekok K, 230
 Demorest ME, 203
 Dreith S, 300
 Drew D, 323
 Duddy D, 295
 Durrant J, 316
- Edwards B, 540
 Emmer MB, 57, 348, 464
 English K, 84, 348
- Fausti SA, 103
 Fisher AL, 36
 Fowler KB, 283
 Fox LG, 12
 Friesen LM, 418
- Gfeller K, 390
 Goebel J, 295
 Gopal KV, 454
- Gould HJ, 411
 Grant KW, 429
 Gravel JS, 190
 Green WB, 91
 Greenwald R, 273, 383
- Halpern J, 523
 Hayes D, 300
 Hecht P, 52
 Henderson JA, 156
 Henry JA, 103, 138
 Holcomb LM, 224
 Holden LK, 203
 Holden TA, 203
 Hosford-Dunn H, 523
 Hymel MR, 36
- Idler C, 52
- Jacobson GP, 76, 156, 514
 Jastreboff MM, 162
 Jastreboff PJ, 162
 Jenstad LM, 23
 Jerger J, 273, 383, 465, 467, 501
 Johnson TW, 484
- Kahn JM, 351
 Kaltenbach JA, 125
 Keith RW, 438
 Kempton JB, 103
 Klemens JJ, 361
 Knutson JF, 390
 Konkle DF, 224
- Leek MR, 475
 Lindley GA IV, 316
- Marion MS, 323
 Martin FN, 46, 64, 489
 Martin JS, 46
 McCaslin DL, 156
 Meikle MB, 138
 Mitchell CR, 103
 Moller AR, 115
 Moncrieff D, 273, 383
 Moodie KS, 230
 Moushegian G, 1
 Mueller HG, 561
 Murray KT, 390
 Musiek F, 467
- Nelson R, 309
 Nerbonne MA, 224
 Nondahl DM, 67
 Nozza RJ, 97
- Olson L, 540
- Palmer CV, 316, 570
 Pass RF, 283
 Pennartz L, 454
 Perez DD, 489
 Peterein J, 295
 Potts LG, 181
 Pratt S, 316
 Pumford JM, 23
- Ricketts T, 561
 Rojas T, 84
 Roush J, 446
 Rubinstein A, 52
 Ruscetta MN, 570
- Schairer KS, 411
 Schuchman G, 181
 Schwab BM, 494
 Scollie SD, 23, 230
 Seewald RC, 23, 230
 Seipel A, 273, 383
 Serpanos YC, 190
 Shannon RV, 418
 Silman S, 57, 348, 464
 Silverman CA, 57, 348, 464
 Simmons JL, 337
 Sininger YS, 309
 Sinks B, 295
 Skinner MW, 203
 Slattery WH III, 418
 Souza PE, 214
 Stockley KB, 91
 Surr RK, 540
- Tasciyan T, 239
 Thornton JM, 330
 Todd NW, 97
 Trautwein PG, 309
 Trune DR, 103
 Tweed TS, 67
 Tyler RS, 390
- Valente M, 181, 295
 Vernon JA, 293
- Walden BE, 429, 475, 540
 Wambacq I, 273, 383
 Webb TM, 323
 Wildmo L, 464
 Wiley TL, 67
 Witt S, 390
 Wright JD, 283
 Wynne MK, 351
- Yellin MW, 484

Subject Index

- AAI. *See* Aided Audibility Index
 ABR. *See* Auditory brainstem response
 Acoustic admittance, 97–102
 Acquired bilateral peripheral vestibular system impairment, 514–520
 AEP. *See* Auditory evoked potential
 AERP. *See* Auditory event-related potential
- Aging, 383–389
 AI. *See* Articulation Index
 Aided Audibility Index (AAI), 214–222, 223
 AIED. *See* Autoimmune inner ear disease
 American National Standards Institute (ANSI), 64–66, 67–74
 Amplification
 nonlinear, 214–222, 223
 satisfaction with, 523–539
- ANSI. *See* American National Standards Institute
 Anticipatory strategy training, 52–55
 APDs. *See* Auditory processing disorders
 Articulation Index (AI), 224–228, 229
 Attention, 257–258
 Audibility, 214–222, 223

- Auditory brainstem response (ABR)
 in children, 284, 286
 selective serotonin reuptake inhibitors and, 454–462
 from tone bursts, 103–112
- Auditory distraction, 36–44
- Auditory event-related potential (AERP), 36–44
- Auditory evoked potential (AEP), 1–9, 12–21, 36–44
- Auditory nervous system, 122, 128
- Auditory neuropathy, 309–314, 337–346
- Auditory neuroscience, 239–263
- Auditory processing disorders (APDs)
 in children, 57–62, 348–349, 438–445, 464–465, 467–473
 reduced motivation in, 57–62, 464–465
 selective serotonin reuptake inhibitors and, 454–462
See also Central auditory processing disorder
- Auditory temporal processing, 501–512
- Aural acoustic admittance measures, 97–102
- Autoimmune inner ear disease (AIED), 361–367
- Balance disability, 76–82
- Balance Function Test (BFT), 76–82
- Behind-the-ear (BTE) hearing aids, 23–35, 181–189, 562–569, 575
- BFT. *See* Balance Function Test
- Bilateral peripheral vestibular system impairment, 514–520
- Binaural interaction tests, 1–9
- Binaural interference, 494–500
- Brain map, 36–44
- BTE. *See* Behind-the-ear (BTE) hearing aids
- Bursting, 131
- BZ5 hearing aid, 540–559
- CAPD. *See* Central auditory processing disorder
- Capillaries, 252
- Categorical loudness judgments, 570–574
- Central auditory processing disorder (CAPD)
 children with, 57–62, 348–349, 464–465
 mismatch negativity and, 12–21
- Central nervous system (CNS), 120–122, 239–263
- Cerumen, 352–353
- Cervico-ocular reflex (COR), 519–520
- Children
 auditory brainstem response in, 284, 286
 with auditory processing disorder, 57–62, 348–349, 438–445, 464–465, 467–473
 hearing loss in, 283–289, 291, 300–306
 loudness growth in, 190–201
 preferred listening levels in, 230–237
 reduced motivation in, 57–62, 464–465
 Turner syndrome in, 446–452
 tympanometric measurements in, 97–102
- Chronic pain, 115–123
- Cisplatin, 323–328
- CMM. *See* Cross-modality matching
- CMV. *See* Cytomegalovirus
- CNS. *See* Central nervous system
- Cochlear implants
 auditory neuropathy and, 309–314
 effects of electrode location in, 418–427
 electrical stimulation and, 203–212, 418–427
 music and, 390–405
 tinnitus masking and, 293–294
- Communication Profile for the Hearing Impaired (CPHI), 477–482
- Compression, wide dynamic range, 214–223, 540–559, 570–574
- CON. *See* Continuous tone
- Conductive hearing loss, 446–452
- Connected Speech Test (CST), 543–559
- Consonants, 214–222, 273–282, 422
- CON-SOT-LOT test, 46–50
- Continuous tone (CON), 46–50
- Contour Test of Loudness Perception, 570–574
- COR. *See* Cervico-ocular reflex
- Counseling skills, 84–90, 114
- CPHI. *See* Communication Profile for the Hearing Impaired
- Cross-modality matching (CMM), 190–201
- CST. *See* Connected Speech Test
- Cytomegalovirus (CMV), 283–289, 291, 300–306
- Deafness. *See* Hearing loss
- DHI. *See* Dizziness Handicap Inventory
- DI. *See* Directivity Index
- Dichotic listening, 383–389
- Digital hearing aids, 330–335, 540–559
- Digital signal processing (DSP), 330–335
- Directional hearing aids, 23–35, 540–559, 561–569, 575
- Directivity Index (DI), 561–569, 575
- Distance education, 84–90, 114
- Distortion-product otoacoustic emissions (DPOAEs)
 increased amplitudes, 323–328
 to single and simultaneous tone pairs, 411–417
- Dizziness, 76–82, 516–517
- Dizziness Handicap Inventory (DHI), 76–82, 516–517
- DPOAEs. *See* Distortion-product otoacoustic emissions
- DSP. *See* Digital signal processing
- Dual-microphone hearing instruments, 23–35, 181–189, 540–559
- Dyslexia, 501–512
- Ear impressions, 351–360
- Early Speech Perception (ESP) test, 313–314
- ECHO. *See* Expected Consequences of Hearing aid Ownership
- Echo planar imaging (EPI), 246–247
- Elderly
 auditory distraction in, 36–44
 hearing handicap in, 67–74
- Electrical stimulation, 203–212, 418–422
- Electrodes, 418–427
- Electro-oculography, 276–280
- Electrophysiologic indices, 36–44
- EPI. *See* Echo planar imaging
- ERP. *See* Event-related potential
- ESP. *See* Early Speech Perception (ESP) test
- Event-related functional MRI, 250–252
- Event-related potential (ERP), 36–44, 273–282, 383–389
- Expected Consequences of Hearing aid Ownership (ECHO), 368–382, 407
- FFR. *See* Frequency-following response
- fMRI. *See* Functional magnetic resonance imaging
- Foreign body, 355
- Frequency-following response (FFR), 1–9
- Functional magnetic resonance imaging (fMRI), 239–263
- GN ReSound digital BZ5 hearing aid, 540–559
- Gradient-recalled echo (GRE), 246
- GRE. *See* Gradient-recalled echo
- Group delay, 330–335
- Handicap
 dizziness, 76–82, 516–517
 tinnitus, 156–160
See also Hearing handicap
- HAPI. *See* Hearing Aid Performance Inventory
- Hearing aids
 adaptation to loudness and environmental stimuli in newly fitted users, 316–321
 behind-the-ear, 23–35, 181–189, 562–569, 575
 benefits from, 429–436, 475–482, 540–559, 561–569, 575
 digital, 330–335, 540–559
 directional, 23–35, 540–559, 561–569, 575

- fitting, 368–382, 407, 523–539, 570–574
- in-the-ear, 23–35, 181–189, 562–569, 575
- outcome measures, 368–382, 523–539
- Profile of Hearing Aid Performance (PHAP), 318–321
- Hearing handicap
 articulation index and, 224–228, 229
 in elderly, 67–74
 hearing aid benefit and, 475–482
- Hearing Handicap Inventory for the Elderly–Screening (HHIE-S), 67–74
- Hearing in Noise Test (HINT), 23–35, 181–189, 318–321, 478–482, 562–569, 575
- Hearing limits, 64–66
- Hearing loss
 in children, 283–289, 291, 300–306
 conductive, 446–452
 high frequency, 429–436, 561–569, 575
 nonorganic, 46–50
 postlingual, 52–55
 sensorineural, 283–289, 291, 316–321, 361–367, 446–452
See also Hearing aids
- Hematoma, 353–354
- HHIE-S. *See* Hearing Handicap Inventory for the Elderly–Screening
- High frequency hearing loss, 429–436, 561–569, 575
- HINT. *See* Hearing in Noise Test
- Hyperactivity, 122–123, 128
- Hyperacusis, 162–175, 295–299
- Hyperbilirubinemia, 337–346
- IHAFF. *See* Independent Hearing Aid Fitting Forum
- IID. *See* Interaural intensity difference
- Imaging
 echo planar, 246–247
 magnetic resonance, 239–263
- Independent Hearing Aid Fitting Forum (IHAFF), 570–574
- Infants, 97–102
- Inner ear disease, 361–367
- Interaural asymmetry, 383–389
- Interaural intensity difference (IID), 1–9
- Interaural symmetry index (ISI), 280–281
- Interaural time difference (ITD), 1–9
- Interstimulus interval (ISI), 570–574
- In-the-ear (ITE) hearing aids, 23–35, 181–189, 562–569, 575
- ISI. *See* Interaural symmetry index; Interstimulus interval
- ITD. *See* Interaural time difference
- ITE. *See* In-the-ear (ITE) hearing aids
- KEMAR. *See* Knowles Electronics' Mannikin for Auditory Research
- Knowles Electronics' Mannikin for Auditory Research (KEMAR), 572
- LAEP. *See* Late auditory evoked potential
- Late auditory evoked potential (LAEP), 36–44
- Lengthened off-time pulsed tone (LOT), 46–50
- Lexical reading, 501–512
- Listening
 dichotic, 383–389
 habits, 390–406
 levels, 230–237
- List equivalency, 91–95
- LOT. *See* Lengthened off-time pulsed tone
- Loudness
 adaptation to, 316–321
 judgments, 570–574
 matching, 143–148, 156–160, 178, 190–201
 measures, 203–212
- Magnesium deficiency, 323–328
- Magnetic resonance imaging (MRI), 239–263
- Magnetic resonance spectroscopy (MRS), 247–249
- MAL. *See* Maximum acceptable loudness level
- Masking, 140, 148–150, 293–294
- Maximum acceptable loudness level (MAL), 203–212
- Microphone, 23–35, 181–189, 540–559, 561–569, 575
- Middle ear trauma, 351–360
- Mismatch negativity (MMN), 12–21
- MMN. *See* Mismatch negativity
- Motivation, 57–62, 464–465
- MRI. *See* Magnetic resonance imaging
- MRS. *See* Magnetic resonance spectroscopy
- MS. *See* Multiple sclerosis
- Multiple sclerosis (MS), 484–488
- Music, 390–405
- NAL. *See* National Acoustic Laboratories
- National Acoustic Laboratories (NAL), 230–237
- Neuropathy, 309–314, 337–346
- Neurophysiology, 125–134
- Neuroscience, 239–263
- NOHL. *See* Nonorganic hearing loss
- Noise
 Hearing in Noise Test, 23–35, 181–189, 318–321, 478–482, 562–569, 575
 speech recognition in, 273–282, 475–482
See also Signal-to-noise ratio
- N₁ response, 36–44
- Nonlexical reading, 501–512
- Nonlinear amplification, 214–222, 223
- Nonorganic hearing loss (NOHL), 46–50
- Normal hearing limits, 64–66
- Northwestern University
 Auditory Test No. 6, 67–74, 91–95, 489–493, 522
- Nucleus-22 cochlear implant, 418–427
- OAEs. *See* Otoacoustic emissions
- OHC. *See* Outer hair cell
- Otoacoustic emissions (OAEs)
 auditory neuropathy and, 337–346
 in children, 284
 transient evoked, 311–312, 456, 457
See also Distortion-product otoacoustic emissions
- Outcome measures, 523–539
- Outer hair cell (OHC), 323–328, 337–346
- Pain, 115–123
- Pediatrics. *See* Children
- Perilymph fistula, 356–357
- Peripheral vestibular system impairment, 514–520
- PET. *See* Positron emission tomography
- PHAB. *See* Profile of Hearing Aid Benefit
- Phantom perceptions, 262–263
- PHAP. *See* Profile of Hearing Aid Performance
- Phonetic balance, 489–493, 522
- Phonophobia, 166–168, 173–174
- Pitch, 141–143, 146–148
- PLLs. *See* Preferred listening levels
- Positron emission tomography (PET), 259–260, 262
- Postlingual hearing loss, 52–55
- Preferred listening levels (PLLs), 230–237
- PRESTO technique, 245, 247, 252, 261
- Private practice, 523–539
- Profile of Hearing Aid Benefit (PHAB), 429–436, 544–559
- Profile of Hearing Aid Performance (PHAP), 318–321
- Psychoacoustics, 138–153
- PTA. *See* Pure-tone average
- P₃₀₀ response, 36–44
- P₁ response, 36–44
- Pure-tone average (PTA), 64–74
- Quinine, 126, 129–130
- Reading, 501–512
- Residual inhibition, 150–151
- ReSound digital BZ5 hearing aid, 540–559
- SAC. *See* Self-Assessment of Communication
- SADL. *See* Satisfaction with Amplification in Daily Life
- Salicylate, 126, 128–129
- Satisfaction with Amplification in Daily Life (SADL), 523–539
- SCAN-A test, 454–462
- SCAN-C test, 438–445

- Selective serotonin reuptake inhibitors (SSRIs), 454–462
- Self-Assessment of Communication (SAC), 224–228, 229
- Sensorineural hearing loss (SNHL), 283–289, 291, 316–321, 361–367, 446–452
- Serotonin, 454–462
- Signal processing, 330–335
- Signal-to-noise ratio (SNR), 23–35, 181–189, 561–569, 575
- Significant Other Assessment of Communication (SOAC), 224–228, 229
- Simultaneous tone pairs, 411–417
- Single tone pairs, 411–417
- SNHL. *See* Sensorineural hearing loss
- SNR. *See* Signal-to-noise ratio
- SOAC. *See* Significant Other Assessment of Communication
- Sodium salicylate, 128–129
- SOT. *See* Standard off-time pulsed tone
- Sound
intense, 130
See also Noise
- Spectroscopy, 239–263
- Speech
competition, 36–44, 273–282
connected, 543–559
perception, 313–314
See also Speech recognition
- Speech recognition
with dual microphone, 23–35, 548–550
in noise, 273–282, 475–482
with Nucleus-22 cochlear implant, 418–427
tests, 52–55
thresholds, 475–482, 496–500
- Spin echo, 246
- SSRIs. *See* Selective serotonin reuptake inhibitors
- Standard off-time pulsed tone (SOT), 46–50
- Subjective categorical loudness judgments, 570–574
- Susac syndrome, 484–488
- TAC. *See* Test of Auditory Comprehension
- Telephone use, 536, 538
- Temporal discharge, 131–132
- Temporal processing, 501–512
- TEOAEs. *See* Transient evoked otoacoustic emissions
- Test of Auditory Comprehension (TAC), 314
- Test of Memory and Learning (TOMAL), 504–512
- THI. *See* Tinnitus Handicap Inventory
- Tinnitus
chronic pain and, 115–123
hyperacusis and, 162–175
imaging, 259–262
loudness matching, 143–148, 156–160, 178
masking with cochlear implant, 293–294
neurophysiologic mechanisms of, 125–134
pitch, 141–143, 146–148
psychoacoustic measures of, 138–153
reliability testing, 156–160, 178
- Tinnitus Handicap Inventory (THI), 156–160
- Tinnitus Retraining Therapy (TRT), 162–175
- TOMAL. *See* Test of Memory and Learning
- Tone
bursts, 103–112
pairs, 411–417
pulsed, 46–50
pure, 64–74
- Tonotopic organization, 132–133, 255
- Transient evoked otoacoustic emissions (TEOAEs), 311–312, 456, 457
- Trauma, 351–360
- TRT. *See* Tinnitus Retraining Therapy
- Turner syndrome, 446–452
- Tympanic membrane, 351–360
- Tympanometry, 97–102
- VCV. *See* Vowel-consonant-vowel
- VEOG. *See* Vertical electro-oculography
- Vertical electro-oculography (VEOG), 276–280
- Vestibular system, 76–82, 514–520
- Vestibulocular reflex (VOR), 76–82, 514–520
- VIOLA. *See* Visual input/output locator algorithm
- Visual input/output locator algorithm (VIOLA), 570–574
- VOR. *See* Vestibulocular reflex
- Vowel-consonant-vowel (VCV), 214–222, 273–282
- Vowels, 422
- WDRC. *See* Wide dynamic range compression
- Wide dynamic range compression (WDRC), 214–223, 540–559, 570–574
- Word recognition
Northwestern University Auditory Test, 91–93, 489–493, 522
phonetic balance in, 489–493, 522
scores, 494–500